Use of proton pump inhibitors and subsequent risk of celiac disease

Digestive and Liver Disease

Volumn 46, Issue 1, 2014, Pages 36-40

  Lebwohl, Benjamin ^a,b   Spechler, Stuart J ^c   Wang, Timothy C ^a   Green, Peter H R ^a   Ludvigsson, Jonas F ^b,d  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Celiac disease; Proton pump inhibitors; Risk factors

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAFUTIDINE; LANSOPRAZOLE; NIPEROTIDINE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROXATIDINE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; MALE; MIDDLE AGED; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; YOUNG ADULT;

CELIAC DISEASE; PROTON PUMP INHIBITORS; RISK FACTORS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELIAC DISEASE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 84892369385     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.08.128     Document Type: Article

References (45)

1. Green P.H., Cellier C. Celiac disease. New England Journal of Medicine 2007, 357:1731-1743.
2. Rubio-Tapia A., Kyle R.A., Kaplan E.L., et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009, 137:88-93.
3. Catassi C., Kryszak D., Bhatti B., et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Annals of Medicine 2010, 42:530-538.
4. Lohi S., Mustalahti K., Kaukinen K., et al. Increasing prevalence of coeliac disease over time. Alimentary Pharmacology and Therapeutics 2007, 26:1217-1225.
5. Kupfer S.S., Jabri B. Pathophysiology of celiac disease. Gastrointestinal Endoscopy Clinics of North America 2012, 22:639-660.
6. Ivarsson A., Persson L.A., Nystrom L., et al. Epidemic of coeliac disease in Swedish children. Acta Paediatrica 2000, 89:165-171.
7. Welander A., Tjernberg A.R., Montgomery S.M., et al. Infectious disease and risk of later celiac disease in childhood. Pediatrics 2010, 125:e530-e536.
8. Vilppula A., Kaukinen K., Luostarinen L., et al. Increasing prevalence and high incidence of celiac disease in elderly people: a population-based study. BMC Gastroenterology 2009, 9:49.
9. Mukherjee R., Egbuna I., Brar P., et al. Celiac disease: similar presentations in the elderly and young adults. Digestive Diseases and Sciences 2010, 55:3147-3153.
10. Murray J.A., Van Dyke C., Plevak M.F., et al. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol 2003, 1:19-27.
11. Khalili H., Huang E.S., Jacobson B.C., et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. British Medical Journal 2012, 344:372-377.
12. Roberts N.B. Review article: human pepsins - their multiplicity, function and role in reflux disease. Alimentary Pharmacology and Therapeutics 2006, 24:2-9.
13. Mullin J.M., Valenzano M.C., Whitby M., et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Alimentary Pharmacology and Therapeutics 2008, 28:1317-1325.
14. Hopkins A.M., McDonnell C., Breslin N.P., et al. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. Journal of Pharmacy and Pharmacology 2002, 54:341-347.
15. Ludvigsson J.F., Montgomery S.M., Ekbom A., et al. Small-intestinal histopathology and mortality risk in celiac disease. Journal of the American Medical Association 2009, 302:1171-1178.
16. Ludvigsson J.F., Brandt L., Montgomery S.M., et al. Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers. BMC Gastroenterology 2009, 9:19-31.
17. Ludvigsson J.F., Otterblad-Olausson P., Pettersson B.U., et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. European Journal of Epidemiology 2009, 24:659-667.
18. Wettermark B., Hammar N., Fored C.M., et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and Drug Safety 2007, 16:726-735.
19. Stephansson O., Granath F., Svensson T., et al. Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register. Clinical Epidemiology 2011, 3:43-50.
20. Ljung R., Ruck C., Mattsson F., et al. Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: a Swedish population-based case-control study. Journal of Clinical Psychopharmacology 2012, 32:336-340.
21. Jonasson C., Hatlebakk J.G., Lundell L., et al. Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. European Journal of Gastroenterology and Hepatology 2013, 25:531-538.
22. Lo W., Sano K., Lebwohl B., et al. Changing presentation of adult celiac disease. Digestive Diseases and Sciences 2003, 48:395-398.
23. Stene L.C., Honeyman M.C., Hoffenberg E.J., et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. American Journal of Gastroenterology 2006, 101:2333-2340.
24. Marild K., Stephansson O., Montgomery S., et al. Pregnancy outcome and risk of celiac disease in offspring: a nationwide case-control study. Gastroenterology 2012, 142:39-45.
25. Lebwohl B., Green P.H., Murray J.A., et al. Season of birth in a nationwide cohort of coeliac disease patients. Archives of Disease in Childhood 2013, 98:48-51.
26. Tanpowpong P., Obuch J.C., Jiang H., et al. Multicenter study on season of birth and celiac disease: evidence for a new theoretical model of pathogenesis. Journal of Pediatrics 2013, 162:501-504.
27. Ament P.W., Dicola D.B., James M.E. Reducing adverse effects of proton pump inhibitors. American Family Physician 2012, 86:66-70.
28. Miner P., Katz P.O., Chen Y., et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. American Journal of Gastroenterology 2003, 98:2616-2620.
29. Spechler S.J., Sharma P., Traxler B., et al. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. American Journal of Gastroenterology 2006, 101:1964-1971.
30. Untersmayr E., Scholl I., Swoboda I., et al. Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice. Journal of Allergy and Clinical Immunology 2003, 112:616-623.
31. Scholl I., Untersmayr E., Bakos N., et al. Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut allergens in BALB/c mice and humans. American Journal of Clinical Nutrition 2005, 81:154-160.
32. Untersmayr E., Bakos N., Scholl I., et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB Journal 2005, 19:656-658.
33. Pittman F.E., Pollitt R.J. Studies of jejunal mucosal digestion of peptic-tryptic digests of wheat protein in coeliac disease. Gut 1966, 7:368-371.
34. Keck B., Kohler P., Wieser H. Disulphide bonds in wheat gluten: cystine peptides derived from gluten proteins following peptic and thermolytic digestion. Zeitschrift fur Lebensmittel-Untersuchung und -Forschung 1995, 200:432-439.
35. Shan L., Molberg O., Parrot I., et al. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297:2275-2279.
36. Snook J.A., Dwyer L., Lee-Elliott C., et al. Adult coeliac disease and cigarette smoking. Gut 1996, 39:60-62.
37. Kaufmann D., Wilder-Smith C.H., Kempf M., et al. Cigarette smoking, gastric acidity and peptic ulceration. What are the relationships?. Digestive Diseases and Sciences 1990, 35:1482-1487.
38. Kedika R.R., Souza R.F., Spechler S.J. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Digestive Diseases and Sciences 2009, 54:2312-2317.
39. Garcia Rodriguez L.A., Ruigomez A., Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clinical Gastroenterology and Hepatology 2007, 5:1418-1423.
40. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology 2007, 102:2047-2056.
41. Keszthelyi D., Jansen S.V., Schouten G.A., et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Alimentary Pharmacology and Therapeutics 2010, 32:1124-1128.
42. Green P.H., Yang J., Cheng J., et al. An association between microscopic colitis and celiac disease. Clinical Gastroenterology and Hepatology 2009, 7:1210-1216.
43. Theisen J., Nehra D., Citron D., et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. Journal of Gastrointestinal Surgery 2000, 4:50-54.
44. Williams C., McColl K.E. Review article: proton pump inhibitors and bacterial overgrowth. Alimentary Pharmacology and Therapeutics 2006, 23:3-10.
45. Garcia-Mazcorro J.F., Suchodolski J.S., Jones K.R., et al. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiology Ecology 2012, 80:624-636.